Stay updated with breaking news from Michaelj Mcelhaugh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...
WARMINSTER, Pa., May 02, 2024 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with...
ABUS Announces Decrease in Annual Revenue and Net Loss for 2023
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a...
Check out this week’s medical marketing news, people on the move and industry chatter.